Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacment therapy
article
OA: closed
CC0
⤵ 4 in-corpus citations
AI-generated summary
Tibolone, used as a progestogen in postmenopausal women on estrogen therapy, caused endometrial regression without withdrawal bleeding in over half of the cases studied.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
For 176 postmenopausal women on HRT with progestogen addition 'on demand' medroxyprogesterone acetate (MPA), noresthisterone and tibolone were used to protect the endometrium in 214 cases. Tibolone is a gonadomimetic steroid with combined progestogenic and estrogenic effects. In this study tibolone has been used as a progestogen. The results of these three progestogens were compared. The endometrial thickness before and after the use of progestogen was determined by vaginosonography. In 175 out of 214 cases progestogen addition during oestrogen therapy caused endometrial regression. Withdrawal bleeding was observed 166 times. If the endometrial thickness on the onset of progestogen addition was 5 mm or more, in nearly all cases withdrawal bleeding occurred when MPA or norethisterone was used. If tibolone was used, no withdrawal bleeding occurred in over half the cases studied. We report the first observation of induced endometrial regression without withdrawal bleeding.
My notes (saved in your browser only)
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cited by (3)
- Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis 1999
- A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness 2005
- Endometrial thickness assessed by transvaginal ultrasound insufficiently predicts occurrence of hyperplasia during unopposed oestrogen use 1996
References (10)
- W1988870163 via openalex
- W1994185207 via openalex
- W2028109121 via openalex
- W2034169040 via openalex
- W2060066965 via openalex
- W2060284063 via openalex
- W2314604683 via openalex
- W2316834452 via openalex
- W2321712742 via openalex
- W2335535595 via openalex
Cited by (3)
- A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness 2005
- Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis 1999
- Endometrial thickness assessed by transvaginal ultrasound insufficiently predicts occurrence of hyperplasia during unopposed oestrogen use 1996
SciLite annotations
chemicals 14
tibolone
estrogen
progestogen
medroxyprogesterone
acetate
ethisterone
tibolone
tibolone
steroid
tibolone
progestogen
estrogen
norethisterone
tibolone
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- scilite
- last seen: 2026-05-18T04:57:49.680383+00:00
- unpaywall
- last seen: 2026-10-03T06:31:36.481334+00:00
License: CC0
· commercial use OK